Analysed TEVA PHARMACEUTICAL IND LTD (TEVJF:OTCMKTS) News Sources
Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care
08-06-2026
yahoo.com
[Latest] Global Generic Drug Market Size/Share Worth USD 926.54 Billion by 2034 at a 6.55% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
09-06-2026
yahoo.com
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy
10-06-2026
yahoo.com
Alvotech Hits Critical Inflection as Biosimilar Pipeline Nears FDA Decisions
10-06-2026
marketbeat.com
Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical
11-06-2026
yahoo.com
Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?
12-06-2026
fool.com
What is the current price of TEVA PHARMACEUTICAL IND LTD (TEVJF:OTCMKTS)?
The current price of TEVA PHARMACEUTICAL IND LTD (TEVJF:OTCMKTS) is $30.34.
TEVA PHARMACEUTICAL IND LTD (TEVJF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of TEVA PHARMACEUTICAL IND LTD (TEVJF:OTCMKTS) since the previous trading day is $0.15.
TEVA PHARMACEUTICAL IND LTD (TEVJF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of TEVA PHARMACEUTICAL IND LTD (TEVJF:OTCMKTS) since the previous trading day is 0.4969%.
What is the most recent average sentiment score for TEVA PHARMACEUTICAL IND LTD (TEVJF:OTCMKTS)?
The most recent average sentiment score for TEVA PHARMACEUTICAL IND LTD (TEVJF:OTCMKTS) is 75 out of 100.
What is the most recent average sentiment for TEVA PHARMACEUTICAL IND LTD (TEVJF:OTCMKTS)?
The most recent sentiment for TEVA PHARMACEUTICAL IND LTD (TEVJF:OTCMKTS) is .
SEC-8K** Filing Available For TEVA PHARMACEUTICAL IND LTD (TEVJF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.